Cardiovascular Responses in Congestive Heart Failure With Cheyne- Stokes Respiration
NCT ID: NCT00495196
Last Updated: 2010-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2007-06-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
NCT05516290
Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study
NCT02007486
Efficacy of a Streamlined Heart Failure Optimization Protocol
NCT05021419
Non-invasive Ventilation in Patients With Cardiac Heart Failure
NCT05433610
ESCAPE Mechanistic Substudies - Ancillary to ESCAPE
NCT00021957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Experimental lung function test
Administration of several CO2 gas mixtures
2
Experimental lung function test
Administration of several CO2 gas mixtures
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental lung function test
Administration of several CO2 gas mixtures
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LVEF less than or equal to 45%
* Stable condition as defined as no hospital admission or changes to medical therapy within two weeks prior to enrolment
Exclusion Criteria
* Clinically significant asthma requiring therapy
* Significant parenchymal lung disease
* Primary pulmonary hypertension
* Myocardial infarction within three months prior to enrolment
* Patients with cardiac resynchronisation devices and permanent pacemakers
* Anaemic (haemoglobin \< 12g/dL)
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ResMed
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ResMed
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rachel A Coxon, BE/MBiomedE
Role: STUDY_DIRECTOR
ResMed/The University of New South Wales
Klaus Schindhelm, PhD
Role: STUDY_DIRECTOR
ResMed/The University of New South Wales
Jodie Lattimore, PhD
Role: STUDY_DIRECTOR
Royal Prince Alfred Hospital, Sydney, Australia
Ian Wilcox, PhD
Role: PRINCIPAL_INVESTIGATOR
Royal Prince Alfred Hospital/The University of Sydney
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
X07-0079
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.